FRNM NASDAQ
Freenome, Inc.
1W: +1.2%
1M: -20.4%
3M: +18.1%
YTD: +10.6%
$13.04
+0.32 (+2.52%)
After Hours: $13.15 (+0.11, +0.84%)
Weekly Expected Move ±12.4%
$10
$11
$13
$14
$16
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$106.4M
52W Range9.95-17.5
Volume513,069
Avg Volume712,923
Beta0.35
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAaron Elliott
Employees378
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2026-07-21
Websitefreenome.com
3300 Marina Boulevard
Brisbane, CA 94005
US
Brisbane, CA 94005
US
About Freenome, Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Latest News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
GRAIL sets new 52-week high as FDA panel backs cancer test
Freenome GAAP EPS of -$2.59
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Elliott Aaron Matthe | F-InKind | 71,920 | $15.25 | 2026-09-02 |
| Waksal Harlan | C-Conversion | 30,000 | — | 2026-07-20 |
| Waksal Harlan | C-Conversion | 30,000 | — | 2026-07-20 |
| Nuechterlein Carole | 0 | — | 2026-07-20 | |
| Costello Ann Catheri | 0 | — | 2026-07-20 |